

Dublin, Ireland-based Priothera Limited, a developer of orally applied sphingosine 1 phosphate receptor modulators for haematological malignancies, has secured 30 million euros in Series A financing. Fountain Healthcare Partners and HealthCap led the round.
Source: Press Release